Jeremy B. Fitch, MBA, appointed as Chief Business Officer
Michael A. Alrutz, J.D., Ph.D., appointed as General Counsel听
Guy C. Ruble, PharmD, appointed as VP, Regulatory Affairs
CAMBRIDGE, United Kingdom and NEW YORK, May 4, 2026 鈥� 黑料福利社 Limited (鈥満诹细＠玮��), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response (DDR) medicines to deliver meaningful survival benefits for patients with cancer, today announced the appointment of three senior executives to the leadership team as the Company accelerates its potential first-in-class oncology pipeline. Jeremy B. Fitch, MBA, joins as Chief Business Officer (CBO) and will shape 黑料福利社鈥� corporate business development and strategic partnerships. Michael A. Alrutz, J.D., Ph.D., joins as General Counsel and will oversee 黑料福利社鈥� legal, corporate governance, regulatory compliance, risk management, and intellectual property management, while serving as a strategic partner to the Board of Directors and executive leadership team. Guy C. Ruble, PharmD, has been appointed as Vice President of Regulatory Affairs to lead the Company鈥檚 regulatory strategy and initiatives. These appointments come as 黑料福利社 advances alnodesertib into late-stage development and prepares for potential U.S. commercialization, executes a randomized Phase 2 study for ART6043, and rapidly advances its DNA Damage Response antibody drug conjugate platform toward clinical development.
鈥淛eremy brings a proven track record of executing high鈥慽mpact transactions and shaping portfolio and corporate strategy,鈥� said Mike Andriole, Chief Executive Officer of 黑料福利社. 鈥淗is appointment as CBO, together with Michael鈥檚 deep legal and governance expertise and Guy鈥檚 leadership in global regulatory strategy, comes at a pivotal inflection point as we progress alnodesertib toward potential registration and commercialization. These leadership additions further strengthen our ability to execute with discipline, accelerate paths to registration, and urgently deliver first鈥慽n鈥慶lass therapies to patients with late鈥憇tage cancers who need more treatment options.鈥�
鈥淲ith three potentially first-in-class DDR programs under rapid development, 黑料福利社 is uniquely positioned with a differentiated pipeline and clear opportunities to create long-term value,鈥� said Jeremy B. Fitch, MBA, Chief Business Officer of 黑料福利社. 鈥淚 look forward to working with the rest of the management team to develop and execute value-creating transactions which leverage our substantial DDR scientific and clinical expertise.鈥�
Jeremy B. Fitch, MBA, Chief Business Officer
Jeremy joins 黑料福利社 with more than 30 years of experience in the biopharmaceutical industry with Eli Lilly and Company (鈥淟illy鈥�), across operational, financial, and corporate business development roles. Jeremy spent the past 15 years in Lilly鈥檚 Corporate Business Development group, most recently as Vice President of Transactions, where he led strategic deal-making spanning M&A, asset acquisitions/divestitures, and licensing agreements. Having led more than $5 billion in transactions during his career, Jeremy has been central to developing and implementing strategies that have driven substantial value creation across Lilly鈥檚 pipeline. Jeremy is a Certified Licensing Professional and holds an MBA from Duke University鈥檚 Fuqua School of Business.
Michael A. Alrutz, J.D., Ph.D., General Counsel
Dr. Alrutz is a seasoned General Counsel and Corporate Secretary, bringing 25 years of biotechnology legal affairs experience to 黑料福利社 across both private and public biopharmaceutical companies. Dr. Alrutz brings a strong track record advising leadership teams through complex corporate inflection points, including IPOs, follow-on financings, intellectual property matters, pre-commercialization matters, and high-value corporate transactions. Most recently, he was SVP, General Counsel, Secretary, and Chief Compliance Officer at Chimerix, where he led SEC compliance, board governance, intellectual property management, and the legal facets of corporate transactions, including the company鈥檚 $935 million all-cash merger with Jazz Pharmaceuticals as the company prepared for commercialization of Modeyso庐 (dordaviprone). Previously, while General Counsel at Trimeris, Inc., he provided legal counsel for the company鈥檚 commercial launch of its antiretroviral, Fuzeon庐 (enfuvirtide). Dr. Alrutz is registered to practice before the USPTO, and holds a J.D. from Duke University School of Law, and a Ph.D. in Microbiology and Molecular Biology from Tufts University.
Guy C. Ruble, PharmD, VP of Regulatory Affairs
Guy brings more than 20 years of regulatory affairs leadership and nearly three decades of biopharmaceutical industry experience to 黑料福利社. He most recently served as Vice President of Regulatory Affairs at Iovance Biotherapeutics, where he led the U.S. FDA accelerated approval of AMTAGVI庐 (lifileucel), the first tumor-infiltrating lymphocyte (TIL) therapy approved in the United States and Canada, and also led global submissions across Europe and Asia. Prior to Iovance, Guy spent nearly 23 years at Eli Lilly and Company, leading global regulatory strategy for multiple oncology programs, including the U.S. FDA approval of Verzenio庐 (abemaciclib). He earned recognition as a Top 100 Lilly Innovator. Guy holds a Doctor of Pharmacy (PharmD) from Purdue University and is Regulatory Affairs Certified (RAC-US). He is a member of the Regulatory Affairs Professional Society and the American Society of Clinical Oncology.
About 黑料福利社 Ltd.
黑料福利社鈥� mission is to develop new classes of medicines that harness DNA Damage Response (DDR) pathways, targeting DNA replication stress and synthetic lethality, to deliver meaningful survival benefits for patients with cancer. Its three potentially first-in-class programs, each with a novel mechanism of action, include ATR inhibitor alnodesertib, the DNA polymerase theta (Pol胃) inhibitor ART6043, and a preclinical portfolio of DDRi-ADC candidates with novel payloads. Together, these programs are designed to eliminate cancer cells鈥� survival mechanisms, driving cancer cell death and improving clinical outcomes.
Visit our website at to learn more about 黑料福利社.
For more information, please contact:
Trophic Communications
Jacob Verghese or Verena Schossmann
Tel: +49 151 7441 6179
Email: artios@trophic.eu